Home
HOWL
HOWL News

Latest Werewolf Therapeutics Inc. (HOWL) News on October 30, 2025

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

Zacks

6 days ago

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

Zacks

7 days ago

Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why

MT Newswires

22 days ago

Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

GlobeNewswire

22 days ago

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?

Zacks

2 months ago

Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?

Werewolf Therapeutics to Participate in the BIO International Convention

GlobeNewswire

5 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Zacks

5 months ago

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

GlobeNewswire

5 months ago

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

GlobeNewswire

5 months ago

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit

GlobeNewswire

6 months ago

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit

Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024)

Simply Wall St.

6 months ago

Werewolf Therapeutics First Quarter 2025 Earnings: US$0.40 loss per share (vs US$0.39 loss in 1Q 2024)

MT Newswires

6 months ago

Wedbush Adjusts Price Target on Werewolf Therapeutics to $6 From $8, Maintains Outperform Rating

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

GlobeNewswire

6 months ago

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline

Zacks

6 months ago

Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

GlobeNewswire

6 months ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

7 months ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

8 months ago

Werewolf Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

8 months ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

GlobeNewswire

8 months ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Pacira (PCRX) Tops Q4 Earnings Estimates

Zacks

8 months ago

Pacira (PCRX) Tops Q4 Earnings Estimates

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

GlobeNewswire

8 months ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch

Simply Wall St.

9 months ago

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch

Werewolf Therapeutics provides business update, highlights 2025 outlook

TipRanks

10 months ago

Werewolf Therapeutics provides business update, highlights 2025 outlook

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

GlobeNewswire

10 months ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

GlobeNewswire

a year ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

GlobeNewswire

a year ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

GlobeNewswire

a year ago

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks

TipRanks

a year ago

Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

GlobeNewswire

a year ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

a year ago

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

MT Newswires

a year ago

Wedbush Adjusts Price Target on Werewolf Therapeutics to $8 From $9, Maintains Outperform Rating

Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

MT Newswires

a year ago

Werewolf Therapeutics Says Initial Data Show Potential Non-Hodgkin Lymphoma Treatment Increased Therapeutic Window in Phase 1 Clinical Trial

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

GlobeNewswire

a year ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

GlobeNewswire

a year ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

GlobeNewswire

a year ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire

2 years ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

GlobeNewswire

2 years ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy

Zacks

2 years ago

All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

GlobeNewswire

2 years ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

GlobeNewswire

2 years ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%

Zacks

2 years ago

How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%

Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

2 years ago

Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates

Zacks

2 years ago

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

2 years ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

GlobeNewswire

2 years ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

GlobeNewswire

2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Dave's Repurchase of FTX Convertible Note for $71 Million Finalized

PR Newswire

2 years ago

Dave's Repurchase of FTX Convertible Note for $71 Million Finalized

GlobeNewswire

2 years ago

RGC Resources, Inc. Schedules First Quarter 2024 Earnings Call

Investors Could Be Concerned With Utah Medical Products' (NASDAQ:UTMD) Returns On Capital

Simply Wall St.

2 years ago

Investors Could Be Concerned With Utah Medical Products' (NASDAQ:UTMD) Returns On Capital

It Might Not Be A Great Idea To Buy Ames National Corporation (NASDAQ:ATLO) For Its Next Dividend

Simply Wall St.

2 years ago

It Might Not Be A Great Idea To Buy Ames National Corporation (NASDAQ:ATLO) For Its Next Dividend

Third Coast Bancshares Inc (TCBX) Reports Record 2023 Earnings, Net Income Surges 79%

GuruFocus.com

2 years ago

Third Coast Bancshares Inc (TCBX) Reports Record 2023 Earnings, Net Income Surges 79%

Grindrod Shipping Holdings Ltd. Announces Ship Sales

GlobeNewswire

2 years ago

Grindrod Shipping Holdings Ltd. Announces Ship Sales

Piedmont Lithium Inc. (PLL) Stock Drops Despite Market Gains: Important Facts to Note

Zacks

2 years ago

Piedmont Lithium Inc. (PLL) Stock Drops Despite Market Gains: Important Facts to Note

Chuck Royce Increases Stake in Identiv Inc

GuruFocus.com

2 years ago

Chuck Royce Increases Stake in Identiv Inc

Why WW International Stock Bounced 6% Higher Today

Motley Fool

2 years ago

Why WW International Stock Bounced 6% Higher Today

ESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gains

Simply Wall St.

2 years ago

ESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gains

Heron Therapeutics, Inc. (NASDAQ:HRTX) is largely controlled by institutional shareholders who own 52% of the company

Simply Wall St.

2 years ago

Heron Therapeutics, Inc. (NASDAQ:HRTX) is largely controlled by institutional shareholders who own 52% of the company

Hot Stocks Roundup: Why Are People Talking About WW International and Zoom Video Communications Stocks Right Now?

Motley Fool

2 years ago

Hot Stocks Roundup: Why Are People Talking About WW International and Zoom Video Communications Stocks Right Now?

Dave Inc.'s (NASDAQ:DAVE) market cap up US$26m last week, benefiting both retail investors who own 41% as well as insiders

Simply Wall St.

2 years ago

Dave Inc.'s (NASDAQ:DAVE) market cap up US$26m last week, benefiting both retail investors who own 41% as well as insiders

ESS Expands Deployment Footprint in California, Commissions New Project and Advances Energy Center Product Line

Business Wire

2 years ago

ESS Expands Deployment Footprint in California, Commissions New Project and Advances Energy Center Product Line

Blade Air Mobility to Present at 26th Annual Needham Growth Conference

GlobeNewswire

2 years ago

Blade Air Mobility to Present at 26th Annual Needham Growth Conference

Despegar.com, Corp. (NYSE:DESP) is largely controlled by institutional shareholders who own 55% of the company

Simply Wall St.

2 years ago

Despegar.com, Corp. (NYSE:DESP) is largely controlled by institutional shareholders who own 55% of the company

Institutions own 39% of Orange County Bancorp, Inc. (NASDAQ:OBT) shares but individual investors control 39% of the company

Simply Wall St.

2 years ago

Institutions own 39% of Orange County Bancorp, Inc. (NASDAQ:OBT) shares but individual investors control 39% of the company

The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable

Simply Wall St.

2 years ago

The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable

What Makes FinWise Bancorp (FINW) a Good Fit for 'Trend Investing'

Zacks

2 years ago

What Makes FinWise Bancorp (FINW) a Good Fit for 'Trend Investing'

Gambling.com Group to Participate at 26th Annual Needham Growth Conference on January 18

Business Wire

2 years ago

Gambling.com Group to Participate at 26th Annual Needham Growth Conference on January 18

Luna to Present at Needham Growth Conference

Business Wire

2 years ago

Luna to Present at Needham Growth Conference

Business Wire

2 years ago

Franklin Universal Trust ("FT" or the "Fund") Announces Distribution

RCA Accessories To Expand its Presence in the Multi-Billion-Dollar Over-the-Counter Hearing Aid Market with the Launch of Three New Premium RCA Models

PR Newswire

2 years ago

RCA Accessories To Expand its Presence in the Multi-Billion-Dollar Over-the-Counter Hearing Aid Market with the Launch of Three New Premium RCA Models

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

GlobeNewswire

2 years ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Hallador Energy (HNRG): The Biggest Contributor of Cove Street Capital

Insider Monkey

2 years ago

Hallador Energy (HNRG): The Biggest Contributor of Cove Street Capital

RGC Resources, Inc.'s (NASDAQ:RGCO) largest shareholders are retail investors with 45% ownership, institutions own 36%

Simply Wall St.

2 years ago

RGC Resources, Inc.'s (NASDAQ:RGCO) largest shareholders are retail investors with 45% ownership, institutions own 36%

VALNEVA - Declaration of shares and voting rights: December 31, 2023

GlobeNewswire

2 years ago

VALNEVA - Declaration of shares and voting rights: December 31, 2023

Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares

GlobeNewswire

2 years ago

Safe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred Shares

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

GlobeNewswire

2 years ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

VOXX INTERNATIONAL CORPORATION SETS DATE FOR ITS FISCAL 2024 THIRD QUARTER RESULTS AND CONFERENCE CALL

PR Newswire

2 years ago

VOXX INTERNATIONAL CORPORATION SETS DATE FOR ITS FISCAL 2024 THIRD QUARTER RESULTS AND CONFERENCE CALL

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

PR Newswire

2 years ago

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why

Zacks

2 years ago

C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why

Melt Pharmaceuticals Provides Corporate Update

Business Wire

2 years ago

Melt Pharmaceuticals Provides Corporate Update

Perfect Corp. Announces Final Results of Previously Announced Self Tender Offer to Purchase up to 16,129,032 Class A Ordinary Shares for an Aggregate Purchase Price of up to $50,000,000

Business Wire

2 years ago

Perfect Corp. Announces Final Results of Previously Announced Self Tender Offer to Purchase up to 16,129,032 Class A Ordinary Shares for an Aggregate Purchase Price of up to $50,000,000

Business Wire

2 years ago

Franklin Universal Trust ("FT" or the "Fund") Announces Notification of Sources of Distributions

Saratoga Investment Corp. to Report Fiscal Third Quarter 2024 Financial Results and Hold Conference Call

GlobeNewswire

2 years ago

Saratoga Investment Corp. to Report Fiscal Third Quarter 2024 Financial Results and Hold Conference Call

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

GlobeNewswire

2 years ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

Business Wire

2 years ago

Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

Jefferies initiates coverage on Chewy, other pet stocks

Yahoo Finance Video

2 years ago

Jefferies initiates coverage on Chewy, other pet stocks

Reuters

2 years ago

UPDATE 1-Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study

Reuters

2 years ago

Aldeyra Therapeutics' eczema drug succeeds in mid-stage study

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

GlobeNewswire

2 years ago

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

Business Wire

2 years ago

Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis

Business Wire

2 years ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Reviewed Returns to CES with Second Annual AccessABILITY Awards

Business Wire

2 years ago

Reviewed Returns to CES with Second Annual AccessABILITY Awards

Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The Company

Simply Wall St.

2 years ago

Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The Company

Share on Social Networks: